A detailed history of Rhumbline Advisers transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 281,348 shares of RXRX stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
281,348
Previous 226,772 24.07%
Holding current value
$1.95 Million
Previous $2.26 Million 6.64%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$7.35 - $10.05 $401,133 - $548,488
54,576 Added 24.07%
281,348 $2.11 Million
Q1 2024

May 09, 2024

BUY
$9.13 - $15.52 $70,346 - $119,581
7,705 Added 3.52%
226,772 $2.26 Million
Q4 2023

Feb 08, 2024

SELL
$5.09 - $10.79 $10,862 - $23,025
-2,134 Reduced 0.96%
219,067 $2.16 Million
Q3 2023

Nov 09, 2023

SELL
$6.59 - $15.86 $242,340 - $583,235
-36,774 Reduced 14.25%
221,201 $1.69 Million
Q2 2023

Aug 08, 2023

BUY
$4.56 - $9.94 $219,322 - $478,084
48,097 Added 22.92%
257,975 $1.93 Million
Q1 2023

May 11, 2023

BUY
$6.42 - $9.64 $27,548 - $41,365
4,291 Added 2.09%
209,878 $1.4 Million
Q4 2022

Feb 14, 2023

BUY
$7.16 - $12.7 $6,179 - $10,960
863 Added 0.42%
205,587 $1.59 Million
Q3 2022

Nov 10, 2022

BUY
$7.83 - $13.6 $125,734 - $218,388
16,058 Added 8.51%
204,724 $2.18 Million
Q2 2022

Aug 11, 2022

BUY
$5.04 - $9.26 $326,460 - $599,807
64,774 Added 52.28%
188,666 $1.54 Million
Q1 2022

May 12, 2022

BUY
$6.16 - $18.03 $29,678 - $86,868
4,818 Added 4.05%
123,892 $887,000
Q4 2021

Feb 10, 2022

BUY
$16.14 - $21.86 $1.51 Million - $2.05 Million
93,790 Added 370.95%
119,074 $2.04 Million
Q3 2021

Nov 12, 2021

BUY
$19.03 - $41.33 $84,987 - $184,579
4,466 Added 21.45%
25,284 $582,000
Q2 2021

Aug 05, 2021

BUY
$18.0 - $37.42 $374,724 - $779,009
20,818 New
20,818 $760,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.25B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.